NCT01604889 2026-04-21
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
Phase 1/2 Terminated
Incyte Corporation
Bristol-Myers Squibb
CytomX Therapeutics
Oslo University Hospital
Bristol-Myers Squibb
Ludwig Institute for Cancer Research
Ardigen
Ardigen
Lytix Biopharma AS